1e
19
1
49
2
2
18
1b
1d
18
3e
44
1d
2 29
1d
25
Edward J. (Jim) Delikatny, Ph.D.
78
44
Research Professor of Radiology
28
71
3
60
Member, Abramson Cancer Center, University of Pennsylvania
96
Member, Institute for Translational Medicine & Therapeutics (ITMAT), University of Pennsylvania
9c
Director, Optical Bioluminescence Sub-Core, Small Animal Imaging Facility, University of Pennsylvania
7e
Member, Institute of Medicine & Engineering, University of Pennsylvania
7b
Director, Small Animal Imaging Facility , University of Pennsylvania
93
Director of Translational Research, Center for Precision Surgery, University of Pennsylvania
11
Department: Radiology
4
1
23
1f
Graduate Group Affiliations
8
b
-
6a
- Pharmacology 41
- Bioengineering e
1d
46
Contact information
58
4
3
3
1d
58
Hospital of the University of Pennsylvania
1f Department of Radiology
26 317 Anatomy Chemistry Building
35 3620 Hamilton Walk
Philadelphia, PA 19104
26
1f Department of Radiology
26 317 Anatomy Chemistry Building
35 3620 Hamilton Walk
Philadelphia, PA 19104
30
Office: (215) 898-3105
30
9f
12
30
18
Publications
23 a
3
2
29
23 a
Links
99 Search PubMed for articles
51 Pharmacological Sciences graduate group faculty webpage.
da Small Animal Imaging Facility
fc Dept of Radiology Lab Description
c
4
b
1f
99 Search PubMed for articles
51 Pharmacological Sciences graduate group faculty webpage.
da Small Animal Imaging Facility
fc Dept of Radiology Lab Description
c
13
Education:
21 a B.Sc. 2c (Chemistry/Environmental Studies) c
2f University of Winnipeg, 1978.
21 a Ph.D. 1f (Physical Chemistry) c
37 University of British Columbia, 1987.
c
3
3
3
3
8b
Permanent link21 a B.Sc. 2c (Chemistry/Environmental Studies) c
2f University of Winnipeg, 1978.
21 a Ph.D. 1f (Physical Chemistry) c
37 University of British Columbia, 1987.
c
2 29
21
1e
1d
24
5e
43c The main interest of this group is the non invasive detection of metabolic changes that occur during tumor development and in response to anticancer drugs in models of human breast cancer. We employ a number of imaging modalities that include near infrared fluorescence optical imaging, MRI and MRS, PET and Cerenkov imaging. We have an active program in the design, synthesis and characterization of NIR optical contrast agents for the detection of phospholipase and choline kinase expression and activity in tumors and for the detection of pH and redox changes in the tumor microenvironment. Changes in lipid metabolite levels are monitored using MRS to determine potential biochemical markers for the detection of tumors and their early response to therapy and correlated with near-infrared optical imaging using enzyme-activated fluorescent contrast agents to detect enzyme activity in situ. We are pioneering the development of Cerenkov imaging by creating novel radiolabeled probes suitable for determining both location and function using dual PET and optical imaging.
6e
e 29
27
Description of Research Expertise
2c Research Interest Summary:43c The main interest of this group is the non invasive detection of metabolic changes that occur during tumor development and in response to anticancer drugs in models of human breast cancer. We employ a number of imaging modalities that include near infrared fluorescence optical imaging, MRI and MRS, PET and Cerenkov imaging. We have an active program in the design, synthesis and characterization of NIR optical contrast agents for the detection of phospholipase and choline kinase expression and activity in tumors and for the detection of pH and redox changes in the tumor microenvironment. Changes in lipid metabolite levels are monitored using MRS to determine potential biochemical markers for the detection of tumors and their early response to therapy and correlated with near-infrared optical imaging using enzyme-activated fluorescent contrast agents to detect enzyme activity in situ. We are pioneering the development of Cerenkov imaging by creating novel radiolabeled probes suitable for determining both location and function using dual PET and optical imaging.
6e
Description of Other Expertise
bf NIR optical imaging, contrast agent design, fluorescence guided surgery, MR spectroscopy, MR imaging, Cerenkov imaging, anticancer drugs, lipid metabolism, cancer pharmacologye 29
23
13f Kelly CL, Wydrzynska M, Phelan MM, Osharovich S, Delikatny EJ, Sée V, Poptani H. : Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239. Metabolites 15(2): 76, Jan 2025.
9a Kennedy GT, Azari FS, Chang A, Bou-Samra P, Desphande C, Predina J, Delikatny EJ, Olson M, Rice DC, Singhal S. c4 : A Phase 2 Multicenter Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer with a pH-Activatable Nanoprobe. Mol Imaging Biol 26(4): 585-592, Aug 2024.
14d Hart MC, Isuri RK, Ramos D, Osharovich SA, Rodriguez AE, Harmsen S, Dudek GC, Huck JL, Holt DE, Popov AV, Singhal S, Delikatny EJ: Non-Small Cell Lung Cancer Imaging Using a Phospholipase A2 Activatable Fluorophore. Chem Biomed Imaging 2(7): 490-500, Jun 2024.
af Bou-Samra P, Chang A, Guo E, Azari F, Kennedy G, Din A, Pechet T, Jarrar D, Kucharczuk J, Predina J, Delikatny J, Low PS, Singhal S b8 Format: Histology and Lung Nodule Fluorescence in Intraoperative Molecular Imaging With Pafolacianine. Ann Thorac Surg Short Rep 2(3): 342-437, Mar 2024.
77 Hsu JC, Barragan D, Tward AE, Hajfathalian M, Amirshaghaghi A, Mossburg KJ, 132 Rosario-Berríos DN, Bouché M, Andrianov AK, Delikatny EJ, Cormode DP: A biodegradable "one-For-all" nanoparticle for multimodality imaging and enhanced photothermal treatment of breast cancer Adv Healthc Mater 13(8): e2303018, Mar 2024 Notes: doi: 10.1002/adhm.202303018.
77 Kennedy GT, Azari FS, Chang A, Chang A, Bou-Samra P, Desphande C, Delikatny 109 EJ, Eruslanov E, Kucharczuk JC, Rice DC, Singhal S: A pH-Activatable nanoprobe labels diverse histologic subtypes of human lung cancer during resection. Mol Imaging Biol 25(5): 824-833, Oct 2023 Notes: doi: 10.1007/s11307-023-01853-2.
72 Azari F, Zhang K, Kennedy G, Bou-Samra P, Chang A, Nadeem B, Chang A, 17b Galandarova A, Ibrahimli A, Karimov Z, Din A, Kucharczuk J, Doraid J, Pechet T, Delikatny E, Singhal S.: Prospective validation of tumor folate receptor expression density with the association of pafolacianine fluorescence during intraoperative molecular imaging-guided lung cancer resections. Eur J Nucl Med Mol Imaging 50(8): 2453-2465, Jul 2023.
72 Azari F, Kennedy GT, Chang A, Nadeem B, Bou-Samra P, Chang A, Segil A, 157 Bernstein E, Sullivan NT, Eruslanov E, Delikatny J, Singhal S: Sodium multivitamin transporter-targeted fluorochrome facilitates enhanced metabolic evaluation of tumors through Coenzyme-R dependent intracellular signaling pathways. Mol Imaging Biol 25(3): 569-585, Jun 2023 Notes: doi:10.1007/s11307-022-01792-4.
77 Bhaduri S, Kelly CL, Lesbats C, Sharkey J, Ressel L, Mukherjee S, Platt MD, e3 Delikatny EJ, Poptani H: Metabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models: In vivo MRS in rodent models. NMR Biomed 36(3): e4855, Mar 2023.
2c
7
1d
1f
Selected Publications
149 Isuri RK, Williams J, Rioux D, Dorval P, Chung W, Dancer PA, Delikatny EJ: Clinical Integration of NIR-II Fluorescence Imaging for Cancer Surgery: A Translational Evaluation of Preclinical and Intraoperative Systems. Cancers (Basel) 17(16): 2676, Aug 2025.13f Kelly CL, Wydrzynska M, Phelan MM, Osharovich S, Delikatny EJ, Sée V, Poptani H. : Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239. Metabolites 15(2): 76, Jan 2025.
9a Kennedy GT, Azari FS, Chang A, Bou-Samra P, Desphande C, Predina J, Delikatny EJ, Olson M, Rice DC, Singhal S. c4 : A Phase 2 Multicenter Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer with a pH-Activatable Nanoprobe. Mol Imaging Biol 26(4): 585-592, Aug 2024.
14d Hart MC, Isuri RK, Ramos D, Osharovich SA, Rodriguez AE, Harmsen S, Dudek GC, Huck JL, Holt DE, Popov AV, Singhal S, Delikatny EJ: Non-Small Cell Lung Cancer Imaging Using a Phospholipase A2 Activatable Fluorophore. Chem Biomed Imaging 2(7): 490-500, Jun 2024.
af Bou-Samra P, Chang A, Guo E, Azari F, Kennedy G, Din A, Pechet T, Jarrar D, Kucharczuk J, Predina J, Delikatny J, Low PS, Singhal S b8 Format: Histology and Lung Nodule Fluorescence in Intraoperative Molecular Imaging With Pafolacianine. Ann Thorac Surg Short Rep 2(3): 342-437, Mar 2024.
77 Hsu JC, Barragan D, Tward AE, Hajfathalian M, Amirshaghaghi A, Mossburg KJ, 132 Rosario-Berríos DN, Bouché M, Andrianov AK, Delikatny EJ, Cormode DP: A biodegradable "one-For-all" nanoparticle for multimodality imaging and enhanced photothermal treatment of breast cancer Adv Healthc Mater 13(8): e2303018, Mar 2024 Notes: doi: 10.1002/adhm.202303018.
77 Kennedy GT, Azari FS, Chang A, Chang A, Bou-Samra P, Desphande C, Delikatny 109 EJ, Eruslanov E, Kucharczuk JC, Rice DC, Singhal S: A pH-Activatable nanoprobe labels diverse histologic subtypes of human lung cancer during resection. Mol Imaging Biol 25(5): 824-833, Oct 2023 Notes: doi: 10.1007/s11307-023-01853-2.
72 Azari F, Zhang K, Kennedy G, Bou-Samra P, Chang A, Nadeem B, Chang A, 17b Galandarova A, Ibrahimli A, Karimov Z, Din A, Kucharczuk J, Doraid J, Pechet T, Delikatny E, Singhal S.: Prospective validation of tumor folate receptor expression density with the association of pafolacianine fluorescence during intraoperative molecular imaging-guided lung cancer resections. Eur J Nucl Med Mol Imaging 50(8): 2453-2465, Jul 2023.
72 Azari F, Kennedy GT, Chang A, Nadeem B, Bou-Samra P, Chang A, Segil A, 157 Bernstein E, Sullivan NT, Eruslanov E, Delikatny J, Singhal S: Sodium multivitamin transporter-targeted fluorochrome facilitates enhanced metabolic evaluation of tumors through Coenzyme-R dependent intracellular signaling pathways. Mol Imaging Biol 25(3): 569-585, Jun 2023 Notes: doi:10.1007/s11307-022-01792-4.
77 Bhaduri S, Kelly CL, Lesbats C, Sharkey J, Ressel L, Mukherjee S, Platt MD, e3 Delikatny EJ, Poptani H: Metabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models: In vivo MRS in rodent models. NMR Biomed 36(3): e4855, Mar 2023.
2c